Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Wednesday, June 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax Pharmaceuticals announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, where CEO Michael A. Metzger will engage in a fireside chat. The event is scheduled for June 12, 2024, at 8:40 a.m. ET, and will be accessible via a live webcast. Syndax is known for its innovative cancer therapy pipeline.
Price reaction · baseline $18.82 (2024-06-04 close) · hit after-hours · 1 other SNDX headline(s) in the window, move may be shared
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax is participating in a major healthcare conference.
  • The company is developing an innovative pipeline of cancer therapies.
  • Live webcast and replay of the event will be available for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

WALTHAM, Mass. , June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 , at 8:40 a.m. ET .
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn .
Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827
SNDX-G

Frequently Asked Questions

When is Syndax participating in the conference?

Syndax will participate in the conference on June 12, 2024.

Who will represent Syndax at the event?

CEO Michael A. Metzger will represent Syndax at the conference.

How can I access the conference webcast?

The live webcast can be accessed from Syndax's Investor section on their website.

What is Syndax known for?

Syndax is known for developing an innovative pipeline of cancer therapies.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Syndax Pharmaceuticals Goldman Sachs healthcare conference cancer therapies Michael A. Metzger
Last updated: Jun 5, 2024

Biotech snapshot

Cash runway
$548M liquidity · $10M/mo burn
~54 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →